Health Canada approves Koselugo for adults with neurofibromatosis type 1
加拿大卫生部已批准阿斯利康的Koselugo（selumetinib）用于治疗患有1型神经纤维瘤和丛状神经纤维瘤的成年患者。
AstraZeneca's Koselugo (selumetinib) has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PNs).
此信号在行业全局中的位置。
AstraZeneca's Datopotamab Deruxtecan Granted Fast Track Designation in US for Metastatic Lung Cancer
AstraZeneca Partners with Jacobio to Co-Develop and Commercialize SHP2 Inhibitors for Cancer Treatment
AstraZeneca's Enhertu Granted US Priority Review for HER2-Positive Early Breast Cancer Post-Neoadjuvant Treatment
AstraZeneca's Evinova partners with Astellas and BMS to speed up clinical trials using its AI platform.
https://www.astrazeneca.com/media-centre/press-releases/2026/koselugo-approved-in-canada-for-adults-with-neurofibromatosis-type-1.html
阅读完整来源精选情报直达收件箱。无垃圾邮件，随时退订。
登录后可保存信号笔记。
登录